Pulmonary cryptococcosis is caused by fungi of the genus Cryptococcus (C. neoformans and C. gattii), which are monomorphic encapsulated yeasts that are found worldwide, particularly in soil contaminated with pigeon droppings and decomposing wood. Although infection occurs through the inhalation of airborne infectious particles, pneumonia is relatively uncommon in infected individuals. In fact, after hematogenous dissemination, infection of the central nervous system is more common than is pneumonia (1–4).

Pulmonary cryptococcosis has a variety of clinical and pathological presentations. It can manifest in immunocompetent and immunocompromised patients, although the latter account for the majority of cases, with a wide variety of radiological abnormalities. The following are the main characteristics to be identified by CT (2–4): location and distribution; solitary or multiple nodules that can progress to confluence or cavitation; segmental consolidation or infiltrative masses; hilar or mediastinal lymph node enlargement; pleural effusion; reticular or nodular infiltrate; linear opacities; septal thickening; and endobronchial lesions. The diagnosis of pulmonary cryptococcosis is difficult to make, because the organisms often colonize the upper airways and the symptoms are nonspecific, as are the radiological manifestations (5,6).

In the diagnosis of pulmonary cryptococcosis, PET/CT plays a complementary role. In approximately 60% of patients, cryptococcal lesions show 18F-fluorodeoxyglucose uptake that is greater than that of the mediastinal blood pool. The SUV, a calculated measure of contrast uptake, is used in order to identify the underlying cause of such lesions, knowledge of their physiological distributions and variants being of fundamental importance for minimizing errors of interpretation (1,5,6). Typically, low SUVs (≤ 2.5) are associated with benign lesions, whereas high SUVs (> 2.5) are associated with malignant lesions (1,5). Sharma et al. (1) demonstrated that the SUVs of cryptococcal lesions range from 0.93 to 11.6.

When PET/CT is used in order to differentiate pulmonary nodules and to discriminate between infection and malignancy, its potential pitfalls should be borne in mind, especially in areas where the prevalence of granulomatous infection is high, as well as in immunocompromised patients (7,8). Inflammatory and infectious lesions can show elevated metabolic rates and can therefore be misidentified as malignant lesions (5,6,8), thus posing a diagnostic challenge (6).

In patients with pulmonary cryptococcosis, there is great variability in the SUVs of cryptococcal lesions. Therefore, the clinical correlation, risk factors for cancer development, and geographic location, together with the PET/CT findings, are fundamental for diagnostic clarification, although it is usually necessary to perform a lung biopsy (1,5,8).

REFERENCES
1. Sharma P, Mukherjee A, Karunanithi S, et al. Potential role of 18F-FDG PET/CT in patients with fungal infections. AJR Am J Roentgenol. 2014;203:180–9.
2. Lindell RM, Hartman TE, Nadrous HF, et al. Pulmonary cryptococcosis: CT findings in immunocompetent patients. Radiology. 2005;236:326–31.
3. Fox DL, Müller NL. Pulmonary cryptococcosis in immunocompetent patients: CT findings in 12 patients. AJR Am J Roentgenol. 2005;185:622–6.
4. Lee WY, Wu JT, Jeng CM, et al. CT findings of pulmonary cryptococcosis: a series of 12 cases. Chin J Radiol. 2005;30:319–25.
5. Truong MT, Ko JP, Rossi SE, et al. Update in the evaluation of the solitary pulmonary nodule. Radiographics. 2014;34:1658–79.
6. Mosmann MP, Borba MA, Macedo FP, et al. Solitary pulmonary nodule and 18F-FDG PET/CT. Part 1: epidemiology, morphological evaluation and cancer probability. Radiol Bras. 2016;49:35–42.
7. Hsu CH, Lee CM, Wang FC, et al. F-18 fluorodeoxyglucose positron emission tomography in pulmonary cryptococcosis. Clín Nucl Med. 2003;28:791–3.
8. Deppen S, Putnam JB Jr, Andrade G, et al. Accuracy of FDG-PET to diagnose lung cancer in a region of endemic granulomatous disease. Ann Thorac Surg. 2011;92:428–32.

Lucas de Pádua Gomes de Farias1, Igor Gomes Padilha2, Márcia Rosana Leite Lemos2, Carla Jotta Justo dos Santos2, Christiana Maria Nobre Rocha de Miranda2
1. Universidade Federal de Alagoas (UFAL), Maceió, AL, Brazil. 2. Clínica de Medicina Nuclear e Radiologia de Maceió (MedRadius), Maceió, AL, Brazil. Mailing address: Dra. Christiana Maria Nobre Rocha de Miranda. Clínica de Medicina Nuclear e Radiologia de Maceió (MedRadius), Rua Hugo Corrêa Paes, 104, Farol. Maceió, AL, Brazil. 57050-730. E-mail: msa.christiana@gmail.com.

Dear Editor,

A 40-year-old female patient, diagnosed 15 years prior with tuberous sclerosis (TS) but not having had periodic follow-up evaluations, presented with a 20-day history of constant abdominal pain. A palpable abdominal mass had been detected during a medical consultation. Laboratory tests revealed no abnormalities. Computed tomography (CT) of the abdomen showed heterogeneous, partially delimitated bulky formations with extensive areas of fat attenuation, resulting in marked bilateral occupation of the kidneys, accompanied by diffuse architectural distortion of the parenchyma and local mass effect (Figure 1). Given the clinical history of the patient, the main diagnostic hypothesis was giant renal angiomyolipomas (AMLs), and the correlation with magnetic resonance imaging (MRI) of the abdomen was therefore recommended (Figure 2). Because of the symptom profile associated with extensive bilateral occupation of the kidneys and the high risk of hemorrhage, it was decided that total nephrectomy was the most appropriate therapeutic option for the patient. Postoperatively, the patient was stable and was referred for routine hemodialysis.

Giant renal angiomyolipomas in a patient with tuberous sclerosis

Masses of the urinary tract have been the object of a number of recent publications in the radiology literature of Brazil (3–5,7). AMLs are rare benign lesions, accounting for 1–3% of all renal tumors, hamartomas being included in the differential diagnosis because of the presence of adipose tissue, neovascularization, and muscle fibers (4). Although the most common type of AML is the sporadic form, 10% of cases are associated with TS, with bilateral distribution and, in some cases, multiple masses. In 60% of cases, patients are asymptomatic, the appearance of symptoms and complications being closely related to the size of the tumor; in symptomatic patients, the most common manifestations are abdominal pain and a palpable mass (5,7).

The diagnosis of AML is typically based on a finding of macroscopic fat in a renal lesion. Classically, AMLs are hyperechoic on ultrasound and are characterized by areas of attenuation below −10 HU on CT. On T1-weighted MRI sequences the areas of fat within the lesions generate signals that are isointense in relation to those of fat present in other organs and hypointense in relation to those of the renal parenchyma. However, the most reliable diagnosis is based on sequences obtained with and without fat suppression. It is not necessary to include the routine use of intravenous contrast administration in diagnostic and
screening protocols for AML (8). Renal biopsy is not indicated, because it increases the risk of serious complications, as well as because the results rarely alter the approach (4).

The aim of treatment is the preservation of renal function. Therefore, the options include arterial embolization, radiofrequency ablation, and surgical procedures aimed at maximum preservation of the renal parenchyma, such as enucleation (9,10).

Surgical intervention becomes necessary when any of the following are identified (5,7): lesions > 4 cm in diameter; pain; active hemorrhage; changes in the tumor; multiple masses, bilateral masses, or a unilateral mass (in a single kidney); and TS. Total nephrectomy should be reserved for restricted cases (7): those in which the majority of the kidney has been occupied by the tumor; those in which a voluminous or solitary lesion is located near the hilum, thus increasing the risk of complications; those in which the results of the imaging examination are inconclusive; those in which there is suspected malignancy; and those in which there is significant retroperitoneal hemorrhage.

In multiple, bilateral renal AMLs accompanied by TS, determining the optimal therapy continues to be a challenge. It is necessary to evaluate the risks for each patient and to establish practices that preserve the renal parenchyma as much as possible. However, in certain cases, such as the one reported here, bilateral nephrectomy is unavoidable.

REFERENCES
1. Sousa CSM, Viana IL, Miranda CLVM, et al. Hemangioma of the urinary bladder: an atypical location. Radiol Bras. 2017;50:271–2.
2. Fernandes AM, Paim BV, Vidal APA, et al. Pheochromocytoma of the urinary bladder. Radiol Bras. 2017;50:199–200.
3. Leite AFM, Venturieri B, Araújo RG, et al. Renal lymphangiectasia: know it in order to diagnose it. Radiol Bras. 2016;49:408–9.
4. Rodríguez WBR, Valbuena JEP, Levi MO. Angiomiolipoma renal gigante y linfangioleiomatosiis pulmonar esporádica no filiada. A propósito de un caso. Urol Colomb. 2014;23:227–32.
5. Palacios RM, Góes ASO, Albuquerque PC, et al. Tratamento endovascular de angiomiolipoma renal por embolização arterial seletiva. J Vasc Bras. 2012;11:324–8.
6. Gomes P, Rebola J, Carneiro R, et al. Esclerose tuberosa: a propósito de um caso clínico. Acta Urológica. 2007;24:39–43.
7. Cerqueira M, Xambre L, Silva V, et al. Angiomiolipoma múltiplo bilateral esporádico – caso clínico. Acta Urológica. 2003;20:63–8.
8. Nelson CP, Sanda MG. Contemporary diagnosis and management of renal angiomyolipoma. J Urol. 2002;168(4 Pt 1):1315–25.
9. Azevedo AS, Simão NMMS. Multicentric angiomyolipoma in kidney, liver, and lymph node: case report/review of the literature. J Bras Patol Med Lab. 2015;51:173–7.
10. Schneider-Monteiro ED, Lucon AM, Figueiredo AA, et al. Bilateral giant renal angiomyolipoma associated with hepatic lipoma in a patient with tuberous sclerosis. Rev Hosp Clin Fac Med S Paulo. 2003;58:103–8.